Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples
Source: SeekingAlpha
2025-08-12 18:43:21 ET
More on Journey Medical
- Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript
- Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript
- Journey Medical GAAP EPS of -$0.18 beats by $0.06, revenue of $13.1M beats by $1.05M
- Journey Medical outlines Emrosi launch momentum and targets expanded payer access in 2025
- Seeking Alpha’s Quant Rating on Journey Medical
Read the full article on Seeking Alpha
For further details see:
Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples
Journey Medical Corporation
NASDAQ: DERM
DERM Trading
-2.47% G/L:
$8.08 Last:
31,404 Volume:
$8.03 Open:
DERM Latest News
December 10, 2025 08:30:00 am
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi(TM) (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
November 12, 2025 04:01:00 pm
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
DERM Stock Data
$266,218,987
14,090,816
2.7%
16
N/A
Pharmaceuticals
Healthcare
US
Scottsdale
